Psychosis in Parkinson’s and Alzheimer’s Disease Market Size (7MM) was valued at ~USD 1290 Million in 2023 and It is projected to grow by 2034

The Psychosis in Parkinson’s and Alzheimer’s Disease Market Size (7MM) was valued at ~USD 1290 Million in 2023 and is projected to grow at a significant CAGR during the study period (2020–2034). DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Psychosis in Parkinson’s and Alzheimer’s Disease Market Landscape. By analyzing historical data, current Psychosis in Parkinson’s and Alzheimer’s Disease Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Psychosis in Parkinson’s and Alzheimer’s Disease Market is increasingly guided by biomarker-driven strategies. Psychosis in Parkinson’s disease and Alzheimer’s disease refers to a group of neuropsychiatric symptoms in which patients lose touch with reality, most commonly experiencing hallucinations (seeing or hearing things that are not present) and delusions (false, fixed beliefs). In Parkinson’s disease, psychosis typically develops in the later stages and is often linked to both the progression of brain changes and the long-term use of dopaminergic medications. Visual hallucinations—such as seeing people, animals, or objects—are especially common, and patients may still retain partial insight early on.

DelveInsight’s report, “Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Psychosis in Parkinson’s and Alzheimer’s Disease Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Psychosis in Parkinson’s and Alzheimer’s Disease Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Psychosis in Parkinson’s and Alzheimer’s Disease Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Psychosis in Parkinson’s and Alzheimer’s Disease Market Forecast

Key Takeaways from Psychosis in Parkinson’s and Alzheimer’s Disease Market Report

• The total diagnosed prevalent cases of Parkinson’s disease in the 7MM were estimated to be 2.6 million in 2023. The US accounted for approximately 45% of the total diagnosed prevalent cases of Parkinson’s disease, while EU4 and the UK accounted for 45%, and Japan for 10% in 2023. These cases are expected to increase by 2034.
• Among the EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases of Parkinson’s disease i.e. 487 thousand, followed by France (223 thousand), while Spain accounted for the lowest number of cases i.e. 150 thousand in 2023.
• In 2023, the total number of diagnosed prevalent cases of Alzheimer's disease in the US accounted for 6.3 million, these cases are expected to change during the forecast period.
• According to estimates based on DelveInsight’s epidemiology model, the age-specific cases of Parkinson's disease in EU4 and the UK in 2023 were, approximately 18 thousand, 62 thousand, 338 thousand, and 773 thousand in the age group <50, 50–59, 60–69, and ≥70 years, respectively. Due to the increase in the overall diagnosed prevalent cases of Parkinson's disease, age-specific cases are expected to increase by 2034.
• According to estimates, females made up about 65% of the total diagnosed cases of Alzheimer’s disease in the US in 2023, while males accounted for the remaining 35%.
• According to DelveInsight analysis, there were 2.1 million diagnosed prevalent cases of Alzheimer's disease psychosis in Japan in 2023, with this number expected to grow at a CAGR of 1.9% by 2034. In contrast, the diagnosed prevalent cases of Parkinson's disease psychosis were reported at 37 thousand in 2023.
• The leading Psychosis in Parkinson’s and Alzheimer’s Disease Companies such as Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others. Promising pipeline candidates include NUPLAZID, Ulotaront, KarXT, ITI-1284, and others.
• Promising Psychosis in Parkinson’s and Alzheimer’s Disease Therapies such as NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.

Psychosis in Parkinson’s and Alzheimer’s Disease Overview

Psychosis in Parkinson’s disease and Alzheimer’s disease can be understood as a condition where individuals experience distorted perceptions or beliefs that do not match reality. This may include seeing things that aren’t there, hearing voices, or strongly believing something untrue. In Parkinson’s disease, these symptoms often appear as the illness progresses and may be influenced by medications used to control movement. Patients commonly report vivid visual hallucinations, sometimes while still being partly aware that what they see isn’t real. In Alzheimer’s disease, psychosis is more closely tied to memory loss and cognitive decline. People may become suspicious, confused about familiar surroundings, or develop false beliefs about others, along with occasional hallucinations.

Get a Free sample for the Psychosis in Parkinson’s and Alzheimer’s Disease Market Report @ https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market

Key Factors in Psychosis in Parkinson’s and Alzheimer’s Disease Therapeutics Market

• Rising Prevalence of Neurodegenerative Disorders

The increasing global burden of Parkinson’s and Alzheimer’s disease is significantly expanding the patient pool prone to psychosis, thereby driving demand for targeted therapeutics.

• Growing Awareness and Diagnosis Rates

Improved recognition of psychosis symptoms among clinicians and caregivers is leading to earlier diagnosis and increased treatment uptake.

• Advancements in Targeted Drug Development

Pharmaceutical companies are focusing on novel mechanisms, including selective serotonin receptor modulators and non-dopaminergic therapies, to address unmet needs with better safety profiles.

• Limitations of Conventional Antipsychotics

Traditional antipsychotic drugs often worsen motor symptoms in Parkinson’s disease or increase mortality risks in elderly Alzheimer’s patients, creating demand for safer, disease-specific therapies.

• Robust Pipeline Activity

A strong pipeline of innovative therapies under clinical development is expected to reshape the treatment landscape and fuel market growth over the forecast period.

• Aging Population Worldwide

The rapid rise in the geriatric population, which is more susceptible to neurodegenerative diseases and associated psychosis, is a major growth driver.

• Increasing Healthcare Expenditure and Access

Improved healthcare infrastructure and spending, especially in emerging markets, are enhancing access to diagnosis and treatment options.

• Regulatory Support and Orphan Drug Incentives

Favorable regulatory pathways and incentives for rare and complex CNS disorders are encouraging drug development and market entry.

• High Unmet Medical Need

The lack of highly effective and well-tolerated treatments for psychosis in these conditions continues to drive research investment and innovation.

• Focus on Improving Quality of Life

Growing emphasis on patient-centric care and reducing caregiver burden is pushing the adoption of effective psychosis management therapies.

Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology Segmentation in the 7MM

The Psychosis in Parkinson’s and Alzheimer’s Disease Market Report proffers epidemiological analysis for the study period 2022-2034 in the 7MM segmented into-

• Diagnosed Prevalent Cases of Parkinson’s disease
• Diagnosed Prevalent Cases of Alzheimer’s disease
• Gender-specific Cases of Parkinson’s disease
• Gender-specific Cases of Alzheimer’s disease
• Age-specific Cases of Parkinson’s disease
• Age-specific Cases of Alzheimer’s disease
• Diagnosed Prevalent Cases of Psychosis in Parkinson’s disease
• Diagnosed Prevalent Cases of Psychosis in Alzheimer’s disease

Download the report to understand which factors are driving Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology trends @ Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology Forecast

Psychosis in Parkinson’s disease and Alzheimer’s disease Market Outlook

Psychosis is also common in most people with Alzheimer’s disease throughout their illness. According to studies, over half of the people with Alzheimer’s disease will experience psychotic symptoms during their illness. Antipsychotic medications are the gold-standard treatment for psychotic episodes and disorders, and the choice, dosing, and administration of the medication largely depend on the scenario. Along with medications, family and caregivers also play an important role in managing psychosis, including providing a safe and therapeutic environment. Along with medications, cognitive behavioral therapy is integral in treating patients with psychotic symptoms and is usually recommended as the initial treatment regime.

Psychosis in Parkinson’s and Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Psychosis in Parkinson’s and Alzheimer’s Disease drugs recently launched in the Psychosis in Parkinson’s and Alzheimer’s Disease market or expected to get launched during the study period. The analysis covers Psychosis in Parkinson’s and Alzheimer’s Disease Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Psychosis in Parkinson’s and Alzheimer’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Psychosis in Parkinson’s disease and Alzheimer’s disease Drugs Market Insights

Pimavanserin is classified as an atypical antipsychotic, specifically known for its unique mechanism of action. Unlike traditional antipsychotics, pimavanserin does not exhibit dopaminergic activity, making it distinctive in its class. It primarily functions as an antagonist and inverse agonist at serotonin receptors, particularly the 5-HT2A and 5-HT2C receptors. This mechanism allows it to manage psychotic symptoms without causing the extrapyramidal side effects commonly associated with other antipsychotic medications. Atypical antipsychotics primarily function by transiently occupying dopamine D2 receptors and rapidly dissociating from them, allowing normal dopamine neurotransmission to resume. This mechanism reduces the risk of extrapyramidal symptoms associated with typical antipsychotics. Additionally, they antagonize serotonin receptors, particularly 5-HT2A, which helps balance dopamine and serotonin levels, effectively addressing both positive and negative symptoms of schizophrenia and mood disorders while minimizing side effects.

To know more about Psychosis in Parkinson’s and Alzheimer’s Disease Companies working in the treatment market, visit @ Psychosis in Parkinson’s and Alzheimer’s Disease Clinical Trials and Therapeutics Assessment

Psychosis in Parkinson’s and Alzheimer’s Disease Market Drivers

• Increasing Disease Burden Worldwide

The growing prevalence of Parkinson’s and Alzheimer’s disease is directly increasing the number of patients experiencing psychosis, driving demand for effective treatments.

• Rapidly Expanding Geriatric Population

Aging populations across major markets are a key contributor, as older individuals are at higher risk of neurodegenerative disorders and associated psychotic symptoms.

• Improved Diagnosis and Clinical Awareness

Enhanced understanding of neuropsychiatric symptoms among healthcare professionals is leading to higher diagnosis rates and timely treatment interventions.

• Rising Demand for Safer Therapies

Safety concerns associated with conventional antipsychotics are encouraging the adoption and development of targeted therapies with improved tolerability.

• Strong Focus on CNS Drug Innovation

Increased research investments in central nervous system disorders are accelerating the development of novel mechanisms addressing psychosis without worsening underlying disease symptoms.

• Expanding Pipeline of Novel Therapeutics

A robust clinical pipeline targeting serotonin pathways and other non-dopaminergic mechanisms is expected to drive future market growth.

• Growing Healthcare Expenditure

Rising healthcare spending across developed and emerging economies is improving access to advanced treatment options.

• Regulatory Support for Unmet Needs

Favorable regulatory pathways and incentives for neurodegenerative and psychiatric conditions are encouraging pharmaceutical companies to invest in this space.

• High Unmet Clinical Need

Limited availability of disease-specific, well-tolerated therapies continues to create strong demand for innovative treatment options.

• Focus on Patient Quality of Life

Increasing emphasis on reducing caregiver burden and improving patient outcomes is boosting the adoption of effective psychosis management therapies.

Psychosis in Parkinson’s and Alzheimer’s Disease Market Barriers

• Limited Availability of Safe and Targeted Therapies

Existing treatment options are scarce and often not specifically designed for psychosis in neurodegenerative disorders, restricting optimal patient outcomes.

• Safety Concerns with Antipsychotic Drugs

Conventional antipsychotics are associated with serious side effects, including worsening motor symptoms in Parkinson’s disease and increased mortality risk in Alzheimer’s patients.

• Underdiagnosis and Misinterpretation of Symptoms

Psychosis is frequently underreported or mistaken for general cognitive decline, leading to delayed diagnosis and reduced treatment adoption.

• Regulatory Challenges in CNS Drug Development

Stringent approval processes, coupled with complex clinical trial requirements in elderly populations, slow down the introduction of new therapies.

• High Clinical Trial Failure Rates

Central nervous system (CNS) drug development carries a high risk of failure due to unclear disease mechanisms and difficulty in demonstrating efficacy.

• Limited Patient Awareness and Social Stigma

Stigma around psychiatric symptoms often discourages patients and caregivers from seeking timely medical help.

• Cost and Reimbursement Constraints

High costs of novel therapies and inconsistent reimbursement policies can limit accessibility, especially in developing regions.

• Complex Disease Pathophysiology

The multifactorial nature of psychosis in neurodegenerative diseases makes it difficult to develop universally effective treatments.

• Caregiver Dependency and Compliance Issues

Patients often rely on caregivers for treatment adherence, and inconsistent caregiving can impact therapy outcomes.

Competition from Off-label and Generic Therapies

Widespread use of inexpensive off-label antipsychotics reduces the adoption of newer, premium-priced therapies.

Scope of the Psychosis in Parkinson’s and Alzheimer’s Disease Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Psychosis in Parkinson’s and Alzheimer’s Disease Companies- Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others. Promising pipeline candidates include NUPLAZID, Ulotaront, KarXT, ITI-1284, and others.
• Psychosis in Parkinson’s and Alzheimer’s Disease Therapies- NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.
• Psychosis in Parkinson’s and Alzheimer’s Disease Therapeutic Assessment: Psychosis in Parkinson’s and Alzheimer’s Disease current marketed and emerging therapies
• Psychosis in Parkinson’s and Alzheimer’s Disease Market Dynamics: Psychosis in Parkinson’s and Alzheimer’s Disease market drivers and Psychosis in Parkinson’s and Alzheimer’s Disease market barriers
• Psychosis in Parkinson’s and Alzheimer’s Disease Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Psychosis in Parkinson’s and Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Psychosis in Parkinson’s and Alzheimer’s Disease Market Access and Reimbursement

Discover more about therapies set to grab the major Psychosis in Parkinson’s and Alzheimer’s Disease Market Share @ Psychosis in Parkinson’s and Alzheimer’s Disease Treatment Market

Table of Contents

1. Key Insights
2. Psychosis in Parkinson’s and Alzheimer’s Disease Market Report Introduction
3. Psychosis in Parkinson’s and Alzheimer’s Disease Executive Summary
4. Psychosis in Parkinson’s and Alzheimer’s Disease Key Events
5. Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology and Market Forecast Methodology
6. Psychosis in Parkinson’s and Alzheimer’s Disease Market Overview at a Glance
7. Psychosis in Parkinson’s and Alzheimer’s Disease Disease Background and Overview
8. Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology and Patient Population
9. Psychosis in Parkinson’s and Alzheimer’s Disease Patient Journey
10. Psychosis in Parkinson’s and Alzheimer’s Disease Marketed Drugs
11. Psychosis in Parkinson’s and Alzheimer’s Disease Emerging Drugs
12. Psychosis in Parkinson’s and Alzheimer’s Disease: 7MM Analysis
13. Psychosis in Parkinson’s and Alzheimer’s Disease Unmet Needs
14. Psychosis in Parkinson’s and Alzheimer’s Disease SWOT Analysis
15. Psychosis in Parkinson’s and Alzheimer’s Disease KOL Views
16. Psychosis in Parkinson’s and Alzheimer’s Disease Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.